Uso práctico de inhibidores de bomba de protones

Barra lateral del artículo

Contenido principal del artículo

Nicolás Zuluaga Arbeláez
  • Biografía

    Universidad CES. Medellín, Colombia.

Óscar Ardila
  • Biografía

    Gastroenterología, Clínica CES. Medellín, Colombia.

Luis Gonzalo Guevara Casallas
  • Biografía

    Postgrado de Gastroenterología, Universidad CES. Medellín, Colombia.

Resumen

Los inhibidores de la bomba de protones (IBP) se encuentran entre los medicamentos más utilizados en el mundo por su bajo costo, extensa prescripción y efectividad. Sin embargo, su uso a largo plazo no es inocuo y aún hay vacíos en el conocimiento del empleo adecuado de estos medicamentos. Por lo tanto, en esta revisión se expone, además de sus propiedades generales, sus verdaderas indicaciones, el uso recomendado a largo plazo y las estrategias para lograr la deprescripción, con el fin de evitar el uso indiscriminado.

Palabras clave:
proton pump inhibitors, pharmacokinetics, deprescription inhibidores de la bomba de protones, farmacocinética, deprescripciones inibidores da bomba de prótons, farmacocinética, deprescripções

Detalles del artículo

Referencias

Drugreport. The 50 most commonly prescribed drugs in America and their average price. Reporting on dangerous drugs, defective medical devices & harmful products [Internet]. 2020 [citado 26 de junio de 2021]. Disponible en: https://www.drugreport.com/50commonlyprescribed- drugs-in-america/

Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015; 314(17):1818-31.

Spechler SJ. Proton pump inhibitors: What the internist needs to know. Med Clin North Am. 2019; 103(1):1-14.

Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008; 10(6):528-34.

Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman: Las bases farmacológicas de la terapéutica. 13.a ed. McGraw-Hill; 2018.

Robinson M. New-generation proton pump inhibitors: Overcoming the limitations of earlygeneration agents. Eur J Gastroenterol Hepatol. 2001; 13(Suppl 1):S43-7.

Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013; 19(1):25-35.

Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: A randomized, three-way crossover study. Aliment Pharmacol Ther. 2004; 20(4):399-406.

Garnett WR. History of acid suppression: Focus on the hospital setting. Pharmacotherapy. 2003; 23(10 Pt 2):56S-60S.

Tringali A, Manta R, Sica M, Bassotti G, Marmo R, Mutignani M. Comparing intravenous and oral proton pump inhibitor therapy for bleeding peptic ulcers following endoscopic management: A systematic review and meta-analysis. Br J Clin Pharmacol. 2017; 83(8):1619-35.

Jiang M, Chen P, Gao Q. Systematic review and net-work meta-analysis of upper gastrointestinal hemorrhage interventions. Cell Physiol Biochem. 2016; 39(6):2477-91.

Yen HH, Yang CW, Su WW, Soon MS, Wu SS, Lin HJ. Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. BMC Gastroenterol. 2012; 12:66.

Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, et al. Relative potency of protonpump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009; 65(1):19-31.

Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018; 16(6):800-808.e7.

Graham DY, Lu H, Dore MP. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter. 2019; 24(1):e12554.

Neumann I, Letelier LM, Rada G, Claro JC, Martin J, Howden CW, et al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2013;(6):CD007999.

Li MJ, Li Q, Sun M, Liu LQ. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. Medicine (Baltimore). 2017;96(39):e8120.

Edwards SJ, Lind T, Lundell L. Systematic review: Proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther. 2006; 24(5):743-50.

Stedman CA, Barclay ML. Review article: Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000; 14(8):963-78.

McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: Esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414-25.

Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: A meta-analysis of randomized clinical trials. Plos One. 2013; 8(4):e62162.

Kukulka M, Nudurupati S, Perez MC. Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe. Clin Exp Gastroenterol. 2018; 11:381-9.

Kinoshita Y, Hongo M, Japan TWICE Study Group. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: The Japan-based TWICE study. Am J Gastroenterol. 2012; 107(4):522-30.

Londong W, Barth H, Dammann HG, Hengels KJ, Kleinert R, Müller P, et al. Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. Aliment Pharmacol Ther. 1991; 5(3):245-54.

Müller P, Simon B, Khalil H, Lühmann R, Leucht U, Schneider A. Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol. 1992; 30(11):771-5.

Hanna S, Rastogi A, Weston AP, Totta F, Schmitz R, Mathur S, et al. Detection of Barrett’s esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol. 2006; 101(7):1416-20.

Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, et al. Management of nonvariceal upper gastrointestinal bleeding: Guideline recommendations from the international consensus group. Ann Intern Med. 2019; 171(11):805-22.

Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: A meta-analysis. Aliment Pharmacol Ther. 2002; 16(6):1149-56.

Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012; 46(2):93-114.

Gill JM, Player MS, Metz DC. Balancing the risks and benefits of proton pump inhibitors. Ann Fam Med. 2011; 9(3):200-2.

Targownik L. Discontinuing long-term ppi therapy: Why, with whom, and how? Am J Gastroenterol. 2018; 113(4):519-28.

Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: Evidence from randomized clinical trials. Clin Ther. 2001; 23(7):998-1017.

Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;(5):CD002095.

Schoepfer AM, Safroneeva E, Bussmann C, Kuchen T, Portmann S, Simon H-U, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013; 145(6):1230-1236.e1-2.

Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134(4):937-44.

Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016; 111(1):30-50.

Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther. 2006; 23(3):437-44.

Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study. Gastroenterology. 1995; 108(6):1637-49.

Pinto-Sánchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017; 11:CD011194.

Zikos TA, Clarke JO. Non-acid reflux: When it matters and approach to management. Curr Gastroenterol Rep. 2020;22(9):43.

Xiao Y, Liang M, Peng S, Zhang N, Chen M. Tailored therapy for the refractory GERD patients by combined multichannel intraluminal impedance-pH monitoring. J Gastroenterol Hepatol. 2016; 31(2):350-4.

Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): A prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003; 98(9):1940-4.

Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after longterm inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005; 21(2):149-54.

Björnsson E, Abrahamsson H, Simrén M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006; 24(6):945-54.

Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001; 121(5):1095-100.

Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of «on-demand» therapy for 6 months. Aliment Pharmacol Ther. 2001; 15(3):347-54.

Bayerdörffer E, Bigard MA, Weiss W, Mearin F, Rodrigo L, Dominguez JE, et al. Randomized, multicenter study: On-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterol. 2016; 16:48.

Garnett WR. Sucralfate-alternative therapy for peptic-ulcer disease. Clin Pharm. 1982; 1(4):307-14.

Murie J, Allen J, Simmonds R, de Wet C. Glad you brought it up: A patient-centred programme to reduce proton-pump inhibitor prescribing in general medical practice. Qual Prim Care. 2012; 20(2):141-8.

Leiman DA, Riff BP, Morgan S, Metz DC, Falk GW, French B, et al. Alginate therapy is effective

treatment for GERD symptoms: A systematic review and meta-analysis. Dis Esophagus. 2017;

(5):1-9.